# OnCo record acerand-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/acerand-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "acerand-therapeutics" ;
  schema:name "Acerand Therapeutics"@en ;
  schema:alternateName "优领医药"@en ;
  schema:description "Acerand Therapeutics develops small-molecule cancer medicines. Its programmes include ACE-232, a tablet that blocks the CYP11A1 enzyme at the start of steroid hormone production, in an early trial for prostate cancer that no longer responds to hormone therapy, and a selective PARP1 inhibitor."@en ;
  schema:url <https://onco.cc/companies/acerand-therapeutics/>, <https://www.acerand.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.acerand.com/>, <https://www.acerand.com/news.html>, <https://clinicaltrials.gov/study/NCT06801236> ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/hormonal/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:targets <https://onco.cc/targets/cyp11a1/>, <https://onco.cc/targets/parp/> .